NEW YORK--(BUSINESS WIRE)--Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched th

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

ARS Pharmaceuticals Investigation Initiated: Levi and Korsinsky Investigates the Officers and Direct

ARS Pharmaceuticals CEO projected CVS Caremark formulary inclusion was expected for the July 1, 2026

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it i

LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Join ARS Pharmaceuticals,

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on Wednesday reaffirmed its expectation to achieve cash-flow

ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, whil

Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperfor

ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spra

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release a

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3

SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spra

Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent

Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overwe

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the an

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening

The CNN Business Fear & Greed Index, a measure of market sentiment, improved slightly on Thursda

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering patient

"The approval of neffy by Health Canada marks a meaningful advancement for the more than 2.5 mil

Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of ag

Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainer

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.42) per share which beat the anal

-Five poster presentations highlight clinical advancement of neffy, real-world usability and advanta

Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company p

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-ris

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's a

Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug app

neffy is the first epinephrine product approved for use out of a hospital setting in China for adult

ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the an

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to